Galaxy Medicare Limited · NSE:GML
Galaxy Medicare — Investor Presentation (October 2026)
31 slides from Galaxy Medicare's investor presentation, Oct 24, 2026
Slide 1: Investor Presentation Intimation Letter to NSE
Ref No : GML/NSE/2026-2027/14 Date: 24th October 2026 To, The Listing Compliance Department National Stock Exchange of India Limited, Exchange Plaza, Plot No. C/1, G Block, Bandra - Kurla Complex, Bandra (East) Mumbai - 400051 NSE SYMBOL: GML ISIN: INE09A801015 Sub: Investor Presentation. Dear Sir/M
Slide 2: Investor Presentation October 2026
INVESTOR P R E S E N TAT I O N October 2026 Delivering Quality. Enhancing Care. 1
Slide 3: Company Overview
Company Overview Leadership, journey, presence, facility, clientele and recognition Galaxy Medicare Limited | Investor Presentation 2
Slide 4: Company at a Glance
Company at a Glance Galaxy Medicare is an integrated medical devices and surgical dressings company engaged in manufacturing, branding, OEM solutions, institutional sales, exports and trading — serving healthcare markets across India and internationally. OUR BUSINESS MODEL Financial Snapshot Own Bra
Slide 5: Board of Directors & Key Management
Board of Directors & Key Management PR O M O T ER S & EX EC U T I V E D I R EC T O R S N O N - EX EC U T I V E & I N D EPEN D EN T D I R EC T O R S Mr. Dillip Kumar Das Mr. Shaswat Kumar Rout Promoter, Chairman & Managing Director Non-Executive & Independent Director Founder promoter (since 1992). F
Slide 6: Our Journey
Our Journey Founded in National Awards for Attained One Star Filed RHP for IPO on Bhubaneswar; revived a Outstanding Export House status NSE EMERGE; capex closed unit (via Entrepreneurship in under Foreign Trade plan approved for IDCO/IPICOL) to make MSEs (Manufacturing) Policy 2023 (DGFT). capacity
Slide 7: Expanding Distribution Footprint & Global Reach
Expanding Distribution Footprint & Global Reach Export sale (₹ Mn) Pan-India Distribution Network 93 98 85 73 FY23 FY24 FY25 FY26 M A R K ET S S ER V ED Domestic — Pan-India FY26 domestic revenue of ₹ 302 Mn, led by Maharashtra (30%) and Gujarat (23%), with balanced coverage across the Rest of India
Slide 8: Our Go-to-Market Channels
Our Go-to-Market Channels Long-standing relationships across four go-to-market channels — a diversified, resilient revenue base built over three decades. FY26 REVENUE SHARE BY CHANNEL Own Brands OEM / Contract (Domestic) Mfg. Pan-India sale of flagship brands via Made to client designs on a principa
Slide 9: Awards & Accolades
Awards & Accolades 2010 Special Recognition National Award 2011 2012 Outstanding Entrepreneurship in Micro & National Award (Third Prize) Best Suggestion Award Small Enterprises (Manufacturing) — Outstanding Entrepreneurship in Small Recognised by the National Productivity Ministry of MSME, Govt. of
Slide 10: Our Clients
Our Clients Trusted by leading medical-device brand owners and OEM partners across India. 3M India Ascent Rupashree Healthcare Medicare Hygiene Limited Prime Medica Promotion Bell Surgical Galaxy Medicare Limited | Investor Presentation 9
Slide 11: Business Overview
Business Overview Business model, product portfolio, end-users, manufacturing process and capacity Galaxy Medicare Limited | Investor Presentation 10
Slide 12: An Integrated Business Model
An Integrated Business Model One integrated manufacturer feeding five routes to market — arrows show how Galaxy’s output flows to each channel. Own-Brand Manufacturing 12 flagship brands; branded, packaged & sold pan-India. Exports Direct exports to UK, Germany, Bangladesh, Nepal & more. OEM / Contr
Slide 13: Product Portfolio
Product Portfolio A comprehensive wound-care, casting and surgical-dressing range — marketed under our own brands and manufactured for OEM clients. 1 2 3 4 Plaster of Paris Bandage B.P. Cotton Crepe Bandage B.P. Elastic Adhesive Bandage B.P. Adhesive Tape U.S.P. 5 6 7 8 Hypoallergenic Microporous Su
Slide 14: Product Mix & End-User Applications
Product Mix & End-User Applications FY26 REVENUE BY PRODUCT END-USER APPLICATIONS Plaster of Paris (POP) Bandage 59% Orthopaedics & Fracture Care Elastic Adhesive Bandage 28% 1 Immobilisation & casting of fractures, joints and deformities. Cannula Fixator 3% Cotton Crepe Bandage 2% Wound Care & Mana
Slide 15: Manufacturing Process — POP Bandage
Manufacturing Process — POP Bandage A mechanised, quality-controlled process (British Pharmacopoeia specifications) with In-Process Quality Control (IPQC) at every stage. 1 Raw-Material QC 2 DOPE / Mass Mixing 3 Spreading & Drying 4 Impregnation → Mother Roll Visual check + BP lab pretesting (settin
Slide 16: Capacity & Utilisation
Capacity & Utilisation Installed capacity across key products with meaningful headroom — supporting growth without proportionate fixed-cost addition. F Y 2 6 CA PA CI T Y U T I LI S A T I O N ( % ) K EY PO I N T S Gypso Chlore 4% Core lines near/above 100% — POP & Elastic Adhesive Bandage — the two
Slide 17: Industry Overview
Industry Overview Market size, growth drivers, trends, government initiatives and regulation Galaxy Medicare Limited | Investor Presentation 16
Slide 18: Large & Growing Addressable Markets
Large & Growing Addressable Markets Galaxy operates across attractive, structurally growing wound-care, casting and surgical-dressing markets — globally and in India. Global Plaster Bandages Global Surgical Dressing India Medical Tapes & Bandages India Wound-Care Management US$3.8bn US$5.95bn ₹2,296
Slide 19: Growth Drivers & Industry Trends
Growth Drivers & Industry Trends G R O W T H D R I V ER S I N D U S T R Y T R EN D S Ageing population & chronic disease Advanced wound-care materials Rising diabetes, ulcers and non-healing wounds increase wound-care demand. Shift to hydrogels, hydrocolloids, foams, alginates & antimicrobial dressi
Slide 20: Government Initiatives & Regulatory Landscape
Government Initiatives & Regulatory Landscape S U PPO R T I V E G O V ER N M EN T I N I T I A T I V ES R EG U LA T O R Y LA N D S C A PE Make in India — Boost to domestic medical-device manufacturing & import substitution. ISO 13485:2016 — Medical-device quality management system certification. PLI
Slide 21: Strategic Overview
Strategic Overview Competitive strengths, growth strategy and investment highlights Galaxy Medicare Limited | Investor Presentation 20
Slide 22: Our Competitive Strengths
Our Competitive Strengths Organisational stability & pedigree Established reputation & relationships Consistent quality standards Three decades of promoter-led operations with deep domain Long-term ties with domestic brand owners and repeat ISO 13485:2016 & CE certified; BP-compliant, in-house QC/QA
Slide 23: Our Growth Strategy
Our Growth Strategy 01 02 03 Enhance capacity & backward integration Grow own-brand & product mix Scale OEM / contract manufacturing Deploy IPO capex on new machinery (incl. pre-cotton cleaning line) Push higher-value SKUs and deepen the 12-brand portfolio across Leverage 3 decades of P2P relationsh
Slide 24: Financial Overview
Financial Overview Financial highlights, income statement, balance sheet, cash flow, key ratios & performance charts Galaxy Medicare Limited | Investor Presentation 23
Slide 25: Income Statement
Income Statement Financials for FY23–FY26. All figures in INR Mn unless stated Particulars (₹ Mn) FY23 FY24 FY25 FY26 Revenue from Operations 312 362 392 400 Operating Expenses 290 313 346 357 EBITDA 22 49 46 43 EBITDA Margin (%) 7.05% 13.54% 11.73% 10.75% Other Income 8 8 11 13 Depreciation 11 5 5
Slide 26: Balance Sheet
Balance Sheet Statement of assets and liabilities · All figures in INR Mn EQUITY & LIABILITIES ASSETS Particulars FY23 FY24 FY25 FY26 Particulars FY23 FY24 FY25 FY26 Equity Share Capital 30 119 119 152 Property, Plant & Equip. 143 144 141 150 Reserves & Surplus 148 95 123 252 Non-Current Investments
Slide 27: Financial Performance
Financial Performance Revenue, profitability and return ratios across FY23–FY26 (INR in Millions). Revenue from Operations (₹ Mn) EBITDA (₹ Mn) & Margin (%) 400 49 392 46 43 362 312 13.54% 22 10.75% 11.73% 7.05% FY23 FY24 FY25 FY26 FY23 FY24 FY25 FY26 PAT (₹ Mn) & Margin (%) 37 34 ROE & ROCE (%) 18.
Slide 28: ESG & Sustainability
ESG & Sustainability Responsible manufacturing, people and governance Galaxy Medicare Limited | Investor Presentation 27
Slide 29: ESG & Sustainability
RESPONSIBILITY ESG & Sustainability Environment Social Governance BP / ISO-aligned processes minimising material waste Skilled & semi-skilled employment in Odisha & West Board with majority independent directors Bengal Moisture-controlled operations reducing rework & Safe, quality-driven medical-dev
Slide 30: Disclaimer
Disclaimer This presentation has been prepared by Galaxy Medicare Limited (the “Company”) solely for information purposes and does not constitute an offer, invitation or solicitation to purchase or subscribe for any securities, nor shall it or any part of it form the basis of, or be relied upon in c
Slide 31: Thank You
G Thank You For any investor-related queries, please reach us at: Galaxy Medicare Limited Plot No-2, Zone D, Phase A, Mancheswar Industrial Estate, Bhubaneswar, Khurda, Mr. Mohd Amir Odisha - 751010 Stock Knocks Mr. Pralaaju Naik Contact: +91 98318 83749 Company Secretary & Compliance Officer Email:
Galaxy Medicare — Investor Presentation (October 2026) on 6ix